TG Therapeutics Inc (TGTX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Michael S. Weiss |
| Employees: | 290 |
| Web site: | tgtherapeutics.com |
|
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
(212) 554-4484
| |
-
Formally known as:
- MANHATTAN PHARMACEUTICALS, INC
- MANHATTAN PHARMACEUTICALS, INC
- TG THERAPEUTICS, INC. NEW COMMON
| Date | Ratio |
|---|---|
| 2011-07-14 | 1:50 |
| 2012-04-30 | 100:5625 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
Please log in first to see chart